BookFrancesco Fraioli, editors.
Summary: This well-illustrated pocket book offers up-to-date guidance on the clinical and research applications of PET/CT in the most common neurological and neuro-oncological disorders. The opening chapters cover the pros and cons of widely used radiological imaging techniques, scanners, and radiopharmaceuticals, with emphasis on the state of the art hybrid modalities, primarily PET/CT but also PET/MRI. Helpful information is provided on the clinical and research tracers used in neurodegenerative diseases, movement disorders, epilepsy and brain tumours. These four killers are then discussed in detail, highlighting the role of PET/CT and targeted tracers in their assessment and in radiotherapy planning. In addition, the clinical applications of PET/MRI are considered. Throughout, many images are included to better explain the diseases and the role of hybrid imaging, and the final chapter presents a large sample of teaching cases and files that will assist in daily clinical practice. The book has been compiled under the auspices of the British Nuclear Medicine Society. It will be an excellent asset for nuclear medicine physicians, radiologists, radiographers, neurologists and neurosurgeons.
Contents:
Intro; Foreword; Preface; Acknowledgements; Contents; Contributors;
1: Introduction to Brain Disorders; References;
2: Radiological Imaging in Brain Disorders: An Overview; 2.1 Neuroimaging Modalities and Techniques; 2.1.1 Computed Tomography (CT); 2.1.2 Magnetic Resonance Imaging (MRI); 2.1.2.1 Perfusion MRI; 2.1.2.2 MR Spectroscopy; 2.1.2.3 Diffusion Tensor Imaging; 2.1.2.4 Functional MRI (f-MRI); 2.2 Radiological Imaging in Neurodegenerative Diseases; 2.3 Radiological Imaging in Movement Disorders; 2.4 Radiological Imaging in Epilepsy; 2.5 Radiological Imaging in Neuro-Oncology 5.3 Frontotemporal Degeneration (FTD)5.4 Dementia of Lewy Body (DLB); 5.5 Other Neurodegenerative Diseases; 5.6 Advantages and Limitations; References;
6: [18F]FDG-PET/CT in Movement Disorders; 6.1 Introduction; 6.2 Parkinson's Disease; 6.2.1 Clinical Phenotypes; 6.2.2 Neuropathology Findings; 6.2.3 [18F]FDG-PET Typical Patterns; 6.3 Multiple System Atrophy; 6.3.1 Clinical Phenotypes; 6.3.2 Neuropathology Findings; 6.3.3 [18F]FDG-PET Typical Patterns; 6.4 The Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration; 6.4.1 Clinical Phenotypes 6.4.2 Neuropathology Findings6.4.3 [18F]FDG-PET Typical Patterns; 6.5 Huntington's Disease; 6.5.1 Clinical Phenotypes; 6.5.2 Neuropathology Findings; 6.5.3 [18F]FDG-PET Typical Patterns; 6.6 Advantages and Limitations; 6.6.1 General Advantages; 6.6.2 General Limitations; References;
7: 18F-FDG PET in Epilepsy; 7.1 Introduction; 7.2 Clinical Indications; 7.3 Classical Patterns; 7.3.1 Temporal; 7.3.2 Extratemporal; 7.3.3 Syndromes; 7.4 Advantages and Limitations; 7.5 Conclusion; References;
8: PET in Neuro-Oncology; 8.1 Introduction 8.2 PET in Primary Glioma Diagnosis and Differential Diagnosis8.2.1 18F-FDG; 8.2.2 11C-MET; 8.2.3 18F-FET; 8.2.4 18F-FDOPA; 8.2.5 18F-CHO; 8.2.6 18F-FLT; 8.3 Amino Acid Tracers PET in Glioma Histological Subtyping; 8.4 PET in Glioma Grading; 8.4.1 18F-FET; 8.4.2 11C-MET; 8.4.3 18F-FDOPA; 8.4.4 18F-FLT; 8.5 Glioma Treatment Effect and Recurrence; 8.6 PET Tracers in Differentiating Recurrence from Treatment Effects; 8.7 Conclusion; References;
9: 18F-FDG PET/CT Indications, Pitfalls and Limitations in Brain Imaging; 9.1 Introduction; 9.2 Indications